Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2021 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Files 2020 Annual Report on Form 20-F

NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
April 30, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update

- NDAs filed in the U.S. and China in Mar. 2021 based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention...
April 28, 2021 16:37 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of...
April 27, 2021 11:22 ET | Source: BeyondSpring, Inc.

BeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
March 31, 2021 23:21 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone ...
March 11, 2021 16:01 ET | Source: BeyondSpring, Inc.

BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

Webinar on Thursday, March 18th @ 10:00 a.m. ET NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical...
December 29, 2020 09:19 ET | Source: BeyondSpring, Inc.

UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
December 29, 2020 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
December 17, 2020 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
December 10, 2020 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone - The plinabulin + pegfilgrastim combination...